T-cell Biofactories

View

This event requires pre-registration:

Pre-registration has ended. You may still attend as a walk-in (if space permit).
Pay at the door $25 in cash or check only

Event includes dinner.

Parijat Bhatnagar – SRI International

Event Information

Event Topic:
T-cell Biofactories

Event Description:
Lack of treatment options for diseases that evade the immune system (e.g., cancer, viral infections, autoimmune disorders) is attributable primarily to their “living” nature. They evolve in vivo, and untargeted therapies given at excessive doses often damage healthy cells. The untenable side effects necessitate early withdrawal of treatment. To address this challenge, we have engineered T-cells capable of modulating their response to the disease target and size. The engineered T-cell will be a “living” vector for synthesizing therapeutic proteins directly at the disease site and proportionate to the disease burden. It can, therefore, be expected that this therapeutic technology will limit side effects, improve quality of life for patients, and reduce the burden on caregivers.

Date/Time:
Date(s) - 07/09/19
6:00 pm - 9:00 pm

Event Location:
Wilson Sonsini Goodrich & Rosati – 650 Page Mill Rd, Palo Alto:

Speaker Information

Event Speaker:
Parijat Bhatnagar

Event Speaker Title:
Program Director, Cell-based Medicine

Event Speaker Company:
SRI International

Event Speaker Bio:

Parijat Bhatnagar, Ph.D. (Program Director, Cell-based Medicine, SRI International, Biosciences Division) has expertise in cell engineering, microfabrication, nanotechnology, and bio-instrumentation.Bhatnagar’s cross-disciplinary interests derive from his career trajectory that spans over cell engineering, semiconductor manufacturing, and industrial engineering. In 2016, he received a National Institute of Health (NIH) Director’s New Innovator Award where is directing his approaches in cell engineering towards viral infections. This award, part of the NIH “High-Risk, High-Reward Research” program, is designed to support scientific investigators with exceptional creativity who are conducting high-impact research.Bhatnagar’s research focus is on the development of platform vector therapeutics based on T cells that can actively seek disease microenvironments, assess the disease burden, and produce a therapeutic response. To accomplish this goal he is engineering cells for specific therapeutic functions and developing bioreactors for clinical cell manufacturing. He is also directing his approaches to engineer cells as sensors for use in companion diagnostics and early detection.Bhatnagar has a PhD in biomedical engineering from Cornell University, Ithaca, NY and completed his postdoctoral training in imaging of adoptively transferred cells from jointly at MD Anderson Cancer Center and Houston Methodist Research Institute. He uses his experience in translation of technologies from laboratory to the factory floor to develop teams with experts within and outside of SRI International. While his experience in translational research and physical sciences has been instrumental in conceptualizing solutions to critical unmet needs, his experience in the industry provides him with the strategy, discipline and rigor to implement these solutions into practice.

Event Details

Cost:
Members $11 who pre-registered; $6- Student/In-transition; General Public $20, Walk-In, $25 (if space permits)